Stoke Therapeutics Inc. (0GT)
XDUS 
Summary
0GT Chart
Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript
Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.4 per share a year ago.
Stoke Therapeutics Q2 Earnings Call Highlights
Stoke Therapeutics NASDAQ: STOK said its Phase III EMPEROR study of zorevunersen in patients with Dravet syndrome remains on track for a data readout in the third quarter of 2027, following completion of enrollment ahead of the company's planned rolling new drug application submission.
Stoke Therapeutics Inc. (0GT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Stoke Therapeutics Inc. ever had a stock split?
Stoke Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ian F. Smith CEO | XDUS Exchange | US86150R1077 ISIN |
| US Country | 170 Employees | - Last Dividend | 6 Jun 2019 Last Split | 19 Jun 2019 IPO Date |
Overview
Stoke Therapeutics, Inc. is an innovative early-stage biopharmaceutical company based in Bedford, Massachusetts, dedicated to developing treatments that address the root causes of severe genetic diseases. Founded in 2014, originally as ASOthera Pharmaceuticals, Inc., the company underwent a name change to Stoke Therapeutics, Inc. in May 2016. With a focus on leveraging its proprietary technology, targeted augmentation of nuclear gene output (TANGO), Stoke Therapeutics is at the forefront of creating antisense oligonucleotides that strategically increase protein levels to counteract genetic deficiencies. The company's collaborative efforts, including a notable agreement with Acadia Pharmaceuticals Inc., emphasize its commitment to uncovering RNA-based medicines for central nervous system disorders and other severe genetic conditions.
Products and Services
- STK-002:
In the preclinical stage, STK-002 is Stoke Therapeutics' leading candidate targeting the treatment of autosomal dominant optic atrophy. Utilizing the company's TANGO platform, STK-002 represents an innovative approach to restoring crucial protein levels to potentially halt or reverse the progression of this genetic eye disease by specifically targeting and correcting the underlying genetic cause.
- STK-001:
Currently in phase I/II clinical trials, STK-001 is aiming to address Dravet syndrome, a severe form of epilepsy. By focusing on the precise genetic mutations that result in Dravet syndrome, STK-001 exemplifies Stoke Therapeutics' commitment to targeted genetic therapies, offering hope for a condition currently lacking in adequate treatments.
- RNA-based Medicines for Neurodevelopmental Diseases:
Under a collaboration with Acadia Pharmaceuticals Inc., Stoke Therapeutics is expanding its horizons into developing novel RNA-based medicines. These treatments are specifically designed to target severe and rare genetic neurodevelopmental diseases affecting the central nervous system. This endeavor underscores the company's broader commitment to addressing haploinsufficiency diseases—conditions where a single functional copy of a gene does not produce enough protein—by exploring the potential of RNA therapies to correct these genetic imbalances.
